MUNICH, Germany – May 5th, 2026 – Adragos Pharma, a global contract development and manufacturing organization (CDMO), today announced the appointment of Konstantinos (Kostas) Rengis as its new Chief Executive officer, succeeding Dr. Andreas Raabe, who founded the company and has led it over the past six years.
Mr. Rengis brings extensive international leadership experience across pharmaceutical manufacturing, R&D and CDMO operations, with a strong track record in leading complex multi-site organizations across Europe, North America, Latin America and Asia. Most recently, he served as Group CEO of FAMAR, where he led a significant transformation of the business and accelerated operational and commercial performance.
“My focus at Adragos is to build on the strong foundations already in place and continue developing a reliable, high-performing organization for our customers, employees, partners and shareholders, working closely with the Board and leadership teams across the organization,” said Mr. Rengis. “This next phase will focus on operational execution, consistent delivery, integration of capabilities across the network, and the continued development of our manufacturing, R&D and commercial activities.”
Since its founding, Adragos has grown into a multinational CDMO operating across six sites in five countries, becoming an established partner in the pharmaceutical outsourcing market. Dr. Raabe will remain a shareholder of Adragos and continue to support the company while shifting his focus from daily operations toward investment activities and advisory support.
“I thank Andreas for his leadership in founding and building Adragos and for laying the groundwork for its next phase,” added Mr. Rengis.
The transition has been structured to ensure full continuity for customers, partners and employees, with a defined handover period to support the continued reliability of Adragos as a long-term partner to its stakeholders.
About Adragos Pharma
Adragos Pharma is a global CDMO headquartered in Munich, Germany, focused on the development and manufacturing of pharmaceutical products. The company operates an international network across Europe and Japan, with capabilities in sterile injectables and complex dosage forms. Adragos operates manufacturing sites in France, Germany, Switzerland, and Japan, as well as a development site in Greece, and is backed by FSN Capital and the Prange Family Office.
